Published on in CHOP News, International Update
In a clinical trial led by a CHOP researcher, adult patients with hemophilia B were able to pursue daily activities without disabling bleeds.
Published on in Beyond Blood
In response to problems in the U.S. healthcare system, the federal government passed a healthcare reform law called the Patient Protection and Affordable Care Act.
Published on in Beyond Blood
Be aware of the signs of caregiver burnout. It may not be obvious to you, may develop over time, and may not be linked to a specific time or event that you can pinpoint.
Published on in Beyond Blood
The primary goal of the Bleeding Disorders Family Advisory Council is to promote communication between the HTC and our families and patients.
Published on in Beyond Blood
Von Willebrand disease (VWD) is a bleeding disorder caused by having too little von Willebrand factor (VWF) protein or VWF that doesn’t work well.
Published on in Beyond Blood
Platelet disorders are an underrecognized cause of bleeding in patients with inherited causes of bleeding. These disorders have only recently become the focus of research efforts.
Published on in Beyond Blood
Genetic testing can help us better estimate risk for inhibitor formation, since inhibitors are more common with certain mutations causing hemophilia.
Published on in Beyond Blood
Children and adolescents with bleeding and clotting disorders (who may be on anticoagulation therapy), picking a sport requires special consideration to minimize risks of bleeding.
Published on in Beyond Blood
In December 2012, CHOP opened a gene therapy clinical trial for patients older than 18 years of age, with factor IX levels equal to or less than 2 percent.
Published on in CHOP News
Researchers at The Children's Hospital of Philadelphia find that a bio-engineered protein shows promise as a new therapy for hemophilia, and may benefit other bleeding disorders.